Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418860
Status:
COMPLETED
Last Update Posted:
2011-08-11
First Post:
2007-01-03
Brief Title:
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease DATE Registry
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DATE
Brief Summary:
The purpose of this study to determine whether the dual antiplatelet therapy aspirin and clopidogrel for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death myocardial infarction or stent thrombosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None